Si-Yang Maggie Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Si-Yang Maggie Liu has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Yi-Long Wu
Southern Medical University
45 shared publications - Qing Zhou
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
39 shared publications - Hai-Yan Tu
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
34 shared publications - Jia-Tao Zhang
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China
34 shared publications - Hong-Hong Yan
Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
32 shared publications - Wei Gao
Geneplus-Beijing Institute, Beijing, China
32 shared publications
Latest Publications
- 26 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (864)
FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36
The prognosis of non–small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in both PC9 and A549 cells. FUS repressed CD36 expression by directly interacting with and destabilizing PPARA ( peroxisome proliferator–activated receptor α) messenger RNA. CD36 augmented fatty acid uptake and oxidative phosphorylation in NSCLC cells. Matrix metallopeptidase 2 (MMP2) was up-regulated through CD36-mediated fatty acid metabolism, which enabled NSCLC cells to disrupt the endothelial barrier. FUS-deficient NSCLC cells increased the expression of neuroendocrine differentiation (NED)–related markers, including SRY-box transcription factor 2 (SOX2), microtubule-associated protein 2 (MAP2), enolase 2 (NSE), and synaptophysin (SYP). They also exhibited neurite-like extensions and expanded in cerebrospinal fluid–supplemented medium in a CD36-dependent manner. Mechanistically, fatty acid uptake increased acetyl-coenzyme A and H3K27ac modifications to promote the expression of NED signature genes and MMP2 in NSCLC cells. Genetic or pharmacological inhibition of CD36 or inhibition of NED-related markers in NSCLC cells hindered LM and prolonged survival in mice. In patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM. Thus, CD36-mediated fatty acid metabolism and NED signature are crucial for progression to LM in NSCLC, highlighting CD36 as a promising therapeutic target to limit the progression of LM.
- 26 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (864)
FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36
The prognosis of non–small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in both PC9 and A549 cells. FUS repressed CD36 expression by directly interacting with and destabilizing PPARA ( peroxisome proliferator–activated receptor α) messenger RNA. CD36 augmented fatty acid uptake and oxidative phosphorylation in NSCLC cells. Matrix metallopeptidase 2 (MMP2) was up-regulated through CD36-mediated fatty acid metabolism, which enabled NSCLC cells to disrupt the endothelial barrier. FUS-deficient NSCLC cells increased the expression of neuroendocrine differentiation (NED)–related markers, including SRY-box transcription factor 2 (SOX2), microtubule-associated protein 2 (MAP2), enolase 2 (NSE), and synaptophysin (SYP). They also exhibited neurite-like extensions and expanded in cerebrospinal fluid–supplemented medium in a CD36-dependent manner. Mechanistically, fatty acid uptake increased acetyl-coenzyme A and H3K27ac modifications to promote the expression of NED signature genes and MMP2 in NSCLC cells. Genetic or pharmacological inhibition of CD36 or inhibition of NED-related markers in NSCLC cells hindered LM and prolonged survival in mice. In patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM. Thus, CD36-mediated fatty acid metabolism and NED signature are crucial for progression to LM in NSCLC, highlighting CD36 as a promising therapeutic target to limit the progression of LM.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. ume 17, 1-12
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
MET amplification is a critical oncogenic driver and a major mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). Currently, next-generation sequencing (NGS)-based assays are increasingly used in clinical practice. However, they lack a unified standard for defining MET amplification across multiple NGS platforms with a potential actionable threshold. This was a multiple-site joint study to optimize the cut-off value for MET amplification using tumor tissue and NGS analysis. In the training cohort, five NGS panels were used to detect MET gene copy number (GCN), and fluorescence in situ hybridization (FISH) was used as a reference. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff with 100% specificity and 66.7% sensitivity. The results were validated in an independent cohort to explore the correlation between MET amplification and efficacy of MET inhibitors in patients with NSCLC. In the training cohort (n=21), the optimal MET GCN cut-off was determined to be 6.55, yielding an area under the curve of 0.9, corresponding to an accuracy of 85.7%. MET polysomy, identified using FISH (n=2), was also detected using NGS. All five NGS panels demonstrated good concordance with FISH, with accuracies ranging from 75.0% to 85.7%. In the validation cohort (n=29), NGS analysis demonstrated a good performance, with an accuracy rate of 79.3%. Patients with MET GCN ≥ 6.55 had a significantly longer median progression free survival than those with MET GCN < 6.55 (hazard ratio = 0.42; p = 0.03). In this study, an exploratory cut-off of 6.55 for MET GCN by NGS was associated with MET amplification and longer progression-free survival in patients receiving targeted therapy. However, given the retrospective design and limited sample size, these findings should be regarded as exploratory and require validation in larger, prospective cohorts before broader clinical application.
- 1 May 2026
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. ume 17, 1-12
Open AccessExploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
MET amplification is a critical oncogenic driver and a major mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). Currently, next-generation sequencing (NGS)-based assays are increasingly used in clinical practice. However, they lack a unified standard for defining MET amplification across multiple NGS platforms with a potential actionable threshold. This was a multiple-site joint study to optimize the cut-off value for MET amplification using tumor tissue and NGS analysis. In the training cohort, five NGS panels were used to detect MET gene copy number (GCN), and fluorescence in situ hybridization (FISH) was used as a reference. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff with 100% specificity and 66.7% sensitivity. The results were validated in an independent cohort to explore the correlation between MET amplification and efficacy of MET inhibitors in patients with NSCLC. In the training cohort (n=21), the optimal MET GCN cut-off was determined to be 6.55, yielding an area under the curve of 0.9, corresponding to an accuracy of 85.7%. MET polysomy, identified using FISH (n=2), was also detected using NGS. All five NGS panels demonstrated good concordance with FISH, with accuracies ranging from 75.0% to 85.7%. In the validation cohort (n=29), NGS analysis demonstrated a good performance, with an accuracy rate of 79.3%. Patients with MET GCN ≥ 6.55 had a significantly longer median progression free survival than those with MET GCN < 6.55 (hazard ratio = 0.42; p = 0.03). In this study, an exploratory cut-off of 6.55 for MET GCN by NGS was associated with MET amplification and longer progression-free survival in patients receiving targeted therapy. However, given the retrospective design and limited sample size, these findings should be regarded as exploratory and require validation in larger, prospective cohorts before broader clinical application.
- Open Access
- 28 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e012071
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases
Background: Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers and fundamental mechanisms. Methods: Patients with NSCLC and BrM planning to receive ICI therapy were enrolled in the prospective cohort, dynamic cerebrospinal fluid (CSF) samples (n=20) were collected through lumbar puncture and used for single-cell RNA sequencing (scRNA-seq), and BrM tumors were collected if they have the indications of surgery, with integrating scRNA-seq data from external database (total n=20). Three independent cohorts underwent flow cytometry (n=8), proteomics analysis (n=31), and multiplex immunohistochemistry (n=25) for validation. Results: Our study provided a high-resolution atlas of cellular dynamics in the CSF and BrM during ICI therapy in patients with NSCLC and BrM. Notably, we identified a key immune cell subset, CD4 + PDCD1 + CXCR6 + T cells, as a positive predictor of ICI intracranial tumor responses, which presented highly functional and transcriptomic similarities in both CSF and BrM tumor environment. Moreover, CXCR6 could serve as a specific marker for CD4 + PDCD1 + T cells linked to ICI response. Further, we revealed that the novel cluster of CD4 + PDCD1 + CXCR6 + T cells was closely associated with lymphocyte activation and aggregation in CSF and BrM of ICI responders, and classical dendritic cells of ICI responders interacted with CD4 + PDCD1 + CXCR6 + T cells for enhanced antigen presentation and inflammatory activation. Conclusion: Our findings revealed critical insights into the immune landscape of NSCLC BrM under ICI therapy, highlighting CD4 + PDCD1 + CXCR6 + T cells in CSF as a promising biomarker and illuminating fundamental mechanisms underlying ICI efficacy.
- 28 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e012071
Open AccessCellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases
Background: Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers and fundamental mechanisms. Methods: Patients with NSCLC and BrM planning to receive ICI therapy were enrolled in the prospective cohort, dynamic cerebrospinal fluid (CSF) samples (n=20) were collected through lumbar puncture and used for single-cell RNA sequencing (scRNA-seq), and BrM tumors were collected if they have the indications of surgery, with integrating scRNA-seq data from external database (total n=20). Three independent cohorts underwent flow cytometry (n=8), proteomics analysis (n=31), and multiplex immunohistochemistry (n=25) for validation. Results: Our study provided a high-resolution atlas of cellular dynamics in the CSF and BrM during ICI therapy in patients with NSCLC and BrM. Notably, we identified a key immune cell subset, CD4 + PDCD1 + CXCR6 + T cells, as a positive predictor of ICI intracranial tumor responses, which presented highly functional and transcriptomic similarities in both CSF and BrM tumor environment. Moreover, CXCR6 could serve as a specific marker for CD4 + PDCD1 + T cells linked to ICI response. Further, we revealed that the novel cluster of CD4 + PDCD1 + CXCR6 + T cells was closely associated with lymphocyte activation and aggregation in CSF and BrM of ICI responders, and classical dendritic cells of ICI responders interacted with CD4 + PDCD1 + CXCR6 + T cells for enhanced antigen presentation and inflammatory activation. Conclusion: Our findings revealed critical insights into the immune landscape of NSCLC BrM under ICI therapy, highlighting CD4 + PDCD1 + CXCR6 + T cells in CSF as a promising biomarker and illuminating fundamental mechanisms underlying ICI efficacy.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S2. Kaplan-Meier Analysis of Disease-Free Survival (DFS) in the Overall Population.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S2. Kaplan-Meier Analysis of Disease-Free Survival (DFS) in the Overall Population.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Purpose:The prognostic value of molecular residual disease (MRD) in non–small cell lung cancer (NSCLC) is well established, with treatment-guiding results anticipated. Here, we present updated analyses from our previously published cohort study of 261 patients with NSCLC undergoing complete resection.Experimental Design:A total of 261 patients with stage I to III lung cancer who underwent radical surgery were enrolled. Enrolled patients underwent follow-up blood draws according to the predefined time points after surgery. As of December 31, 2023, with a median follow-up of 43.4 months, 948 postoperative blood samples were collected.Results:Landmark and longitudinal MRD exhibited positive predictive values of 91.3% and 92.8%, respectively, with a median lead time of 5.2 months. Negative predictive values were 76.5% and 93.2%, respectively. Patients with landmark undetectable MRD could not benefit from adjuvant therapy through the updated follow-up (P = 0.529). Among the 13 patients with recurrent NSCLC and longitudinal undetectable MRD, seven (53.8%) had brain-only metastases, and four (30.8%) had no updated blood samples for over 6 months prior to recurrence. Besides, for those with longitudinal detectable MRD, higher maximum variant allele frequency (>0.55%) and ctDNA level (>13 hGE/mL) were associated with a high risk of short-term recurrence. Additionally, updated follow-up data further support that the peak time for detectable MRD was 18 months after landmark detection.Conclusions:These findings suggest the significant potential of MRD in guiding personalized treatment for NSCLC. Postoperative longitudinal undetectable MRD can indicate a cured population.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Purpose:The prognostic value of molecular residual disease (MRD) in non–small cell lung cancer (NSCLC) is well established, with treatment-guiding results anticipated. Here, we present updated analyses from our previously published cohort study of 261 patients with NSCLC undergoing complete resection.Experimental Design:A total of 261 patients with stage I to III lung cancer who underwent radical surgery were enrolled. Enrolled patients underwent follow-up blood draws according to the predefined time points after surgery. As of December 31, 2023, with a median follow-up of 43.4 months, 948 postoperative blood samples were collected.Results:Landmark and longitudinal MRD exhibited positive predictive values of 91.3% and 92.8%, respectively, with a median lead time of 5.2 months. Negative predictive values were 76.5% and 93.2%, respectively. Patients with landmark undetectable MRD could not benefit from adjuvant therapy through the updated follow-up (P = 0.529). Among the 13 patients with recurrent NSCLC and longitudinal undetectable MRD, seven (53.8%) had brain-only metastases, and four (30.8%) had no updated blood samples for over 6 months prior to recurrence. Besides, for those with longitudinal detectable MRD, higher maximum variant allele frequency (>0.55%) and ctDNA level (>13 hGE/mL) were associated with a high risk of short-term recurrence. Additionally, updated follow-up data further support that the peak time for detectable MRD was 18 months after landmark detection.Conclusions:These findings suggest the significant potential of MRD in guiding personalized treatment for NSCLC. Postoperative longitudinal undetectable MRD can indicate a cured population.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S5. CT and MRI images of patients with brain-only metastases who had longitudinal undetectable MRD. The red arrows indicate the location of metastatic lesions.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S5. CT and MRI images of patients with brain-only metastases who had longitudinal undetectable MRD. The red arrows indicate the location of metastatic lesions.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S4. Kaplan-Meier analysis of the survival time since last blood, comparing patients with longitudinal undetectable MRD to those with longitudinal detectable MRD (last blood draw positive), excluding synchronous recurrences.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S4. Kaplan-Meier analysis of the survival time since last blood, comparing patients with longitudinal undetectable MRD to those with longitudinal detectable MRD (last blood draw positive), excluding synchronous recurrences.